Polymeropoulos Mihael Hristos's Form 4 filing
Vanda Pharmaceuticals Inc. (VNDA) · filed Mar 6, 2024
- Accession no.
- 0000950170-24-027256
- Filed
- Mar 6, 2024
- Trade date
- Mar 4-5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $231.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Polymeropoulos Mihael HristosCIK 0001355537 | Director, Officer (President and CEO), Other: Chairman of the Board |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 4, 2024 | Common Stock | SSaleDisposed | −30,884 | $4.24 | −$130,948.16 | 1,896,018 | Direct | |
| Mar 5, 2024 | Common Stock | SSaleDisposed | −24,288 | $4.13 | −$100,309.44 | 1,871,730 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.